FDA Regulation and the Dynamic Nature of AI
Tuesday, September 15, 2026
Transcript intelligence
What OpenRounds heard
Source-grounded signals extracted from the episode transcript. Timestamps and supporting excerpts appear when available.
The speaker reports that autonomous AI screens for diabetic eye disease without physician image reading as a regulated device, while point-of-care copilots like Open Evidence are used daily by many physicians outside device oversight as clinical decision support
“autonomous ai now screens for diabetic eye disease without a physician reading the image a regulated device at the other end of the spectrum a point of care copilots like open evidence are used now daily by a large share of us physicians they sit outside of as i understand it the device oversight as a clinical decision support”
The speaker reports that the proposed two-stage review for integrated devices first verifies components against standards and then evaluates system performance for market approval.
The speaker reports that small and rural hospitals tend to select more off-the-shelf AI tools due to cost sensitivity and limited staffing, requiring them to be scrappier in purchasing decisions compared to larger health systems.
Dr. Brian Miller has seen medical technology regulation from every side — as a hospitalist, a former FDA official, and now an associate professor at Johns Hopkins University, where he leads a research group on market-driven approaches to FDA regulation and Medicare payment policy. In this episode, Chip talks with Miller about what happens when the FDA applies its 1976 medical device framework to AI — a technology that learns and changes.Miller's argument may surprise you: the manual system of medicine we have today is already less safe and less consistent than most people assume. What keeps him up at night isn't the speed of AI — it's the risk that fear-driven regulation will cost us the opportunities AI offers. The conversation was recorded shortly before the FDA released a discussion paper outlining possible regulatory approaches and inviting stakeholder feedback. Chip weighs in on the paper at the end of the episode. Hosted on Acast. See acast.com/privacy for more information.
Daily healthcare AI brief
Get the free healthcare AI briefing
One concise briefing built from reporting, research, policy, blogs, videos, and full podcast transcripts.
Free. No account needed. Unsubscribe anytime. Already subscribed? Sign in to save and personalize.